Julian Harrison
Stock Analyst at BTIG
(4.98)
# 58
Out of 4,478 analysts
510
Total ratings
58.2%
Success rate
53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintained: Buy | $112 | $86.63 | +29.29% | 22 | Jul 5, 2026 | |
| RNAC Cartesian Therapeutics | Reiterated: Buy | $44 | $10.59 | +315.49% | 10 | Jul 1, 2026 | |
| LQDA Liquidia | Rated: Buy | $109 | $78.93 | +38.10% | 46 | Jul 1, 2026 | |
| ABVX ABIVAX Société Anonyme | Rated: Buy | $150 → $175 | $144.65 | +20.98% | 15 | Jun 30, 2026 | |
| TBPH Theravance Biopharma | Downgraded: Hold | n/a | $16.93 | - | 16 | Jun 29, 2026 | |
| OTLK Outlook Therapeutics | Rated: Hold | $1.61 | $1.45 | +11.03% | 20 | Jun 29, 2026 | |
| INVA Innoviva | Maintained: Buy | $42 | $22.31 | +88.26% | 4 | Jun 22, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintained: Buy | $30 | $18.95 | +58.31% | 32 | Jun 22, 2026 | |
| APGE Apogee Therapeutics | Reiterated: Buy | $137 | $132.91 | +3.08% | 27 | Jun 19, 2026 | |
| CNTB Connect Biopharma Holdings | Maintained: Buy | $10 | $2.46 | +306.50% | 6 | Jun 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 → $20 | $12.90 | +55.04% | 8 | Jun 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 | $17.63 | +115.54% | 24 | Jun 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 → $6 | $4.91 | +22.20% | 16 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $39 → $74 | $21.51 | +244.03% | 18 | Jun 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $151 | $85.21 | +77.21% | 11 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $58 | $18.84 | +207.86% | 10 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $2.02 | +642.57% | 6 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $178 | $71.04 | +150.56% | 17 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $1.24 | +222.58% | 13 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $46 | $31.26 | +47.15% | 6 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1 | $0.3347 | +198.78% | 14 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $555.91 | - | 19 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 | $5.27 | +222.58% | 8 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $61 | $19.40 | +214.43% | 20 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $82 | $131.62 | -37.70% | 32 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.6799 | - | 7 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $0.7713 | n/a | 11 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $161 | $46.95 | n/a | 8 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $11.26 | n/a | 18 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $63.42 | n/a | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $8 | $5.56 | n/a | 16 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $7.74 | n/a | 13 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $150 → $50 | $0.633625 | n/a | 5 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $4 | $0.003 | n/a | 1 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $37.44 | n/a | 3 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $29 | $2.27 | n/a | 2 | Apr 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $1.17 | n/a | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $60 | $4.19 | n/a | 1 | Dec 9, 2020 |
Spyre Therapeutics
Jul 5, 2026
Maintained: Buy
Price Target: $112
Current: $86.63
Upside: +29.29%
Cartesian Therapeutics
Jul 1, 2026
Reiterated: Buy
Price Target: $44
Current: $10.59
Upside: +315.49%
Liquidia
Jul 1, 2026
Rated: Buy
Price Target: $109
Current: $78.93
Upside: +38.10%
ABIVAX Société Anonyme
Jun 30, 2026
Rated: Buy
Price Target: $150 → $175
Current: $144.65
Upside: +20.98%
Theravance Biopharma
Jun 29, 2026
Downgraded: Hold
Price Target: n/a
Current: $16.93
Upside: -
Outlook Therapeutics
Jun 29, 2026
Rated: Hold
Price Target: $1.61
Current: $1.45
Upside: +11.03%
Innoviva
Jun 22, 2026
Maintained: Buy
Price Target: $42
Current: $22.31
Upside: +88.26%
MoonLake Immunotherapeutics
Jun 22, 2026
Maintained: Buy
Price Target: $30
Current: $18.95
Upside: +58.31%
Apogee Therapeutics
Jun 19, 2026
Reiterated: Buy
Price Target: $137
Current: $132.91
Upside: +3.08%
Connect Biopharma Holdings
Jun 17, 2026
Maintained: Buy
Price Target: $10
Current: $2.46
Upside: +306.50%
Jun 11, 2026
Maintained: Buy
Price Target: $19 → $20
Current: $12.90
Upside: +55.04%
Jun 10, 2026
Reiterated: Buy
Price Target: $38
Current: $17.63
Upside: +115.54%
Jun 2, 2026
Maintained: Buy
Price Target: $5 → $6
Current: $4.91
Upside: +22.20%
Jun 1, 2026
Maintained: Buy
Price Target: $39 → $74
Current: $21.51
Upside: +244.03%
May 13, 2026
Maintained: Buy
Price Target: $151
Current: $85.21
Upside: +77.21%
May 13, 2026
Maintained: Buy
Price Target: $58
Current: $18.84
Upside: +207.86%
May 8, 2026
Maintained: Buy
Price Target: $15
Current: $2.02
Upside: +642.57%
May 7, 2026
Maintained: Buy
Price Target: $178
Current: $71.04
Upside: +150.56%
Apr 6, 2026
Maintained: Buy
Price Target: $4
Current: $1.24
Upside: +222.58%
Mar 25, 2026
Maintained: Buy
Price Target: $46
Current: $31.26
Upside: +47.15%
Mar 19, 2026
Maintained: Buy
Price Target: $1
Current: $0.3347
Upside: +198.78%
Feb 25, 2026
Maintained: Hold
Price Target: n/a
Current: $555.91
Upside: -
Feb 20, 2026
Reiterated: Buy
Price Target: $17
Current: $5.27
Upside: +222.58%
Nov 4, 2025
Reiterated: Buy
Price Target: $61
Current: $19.40
Upside: +214.43%
Nov 3, 2025
Maintained: Buy
Price Target: $82
Current: $131.62
Upside: -37.70%
Jul 31, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.6799
Upside: -
Mar 31, 2025
Maintained: Buy
Price Target: $14
Current: $0.7713
Upside: n/a
Mar 17, 2025
Maintained: Buy
Price Target: $161
Current: $46.95
Upside: n/a
Dec 12, 2024
Downgraded: Hold
Price Target: n/a
Current: $11.26
Upside: n/a
Dec 2, 2024
Downgraded: Hold
Price Target: n/a
Current: $63.42
Upside: n/a
Nov 18, 2024
Upgraded: Buy
Price Target: $8
Current: $5.56
Upside: n/a
Nov 13, 2024
Maintained: Buy
Price Target: $24
Current: $7.74
Upside: n/a
Nov 9, 2023
Rated: Buy
Price Target: $150 → $50
Current: $0.633625
Upside: n/a
May 3, 2022
Initiated Coverage: Buy
Price Target: $4
Current: $0.003
Upside: n/a
Apr 28, 2021
Maintained: Buy
Price Target: $12
Current: $37.44
Upside: n/a
Apr 27, 2021
Maintained: Buy
Price Target: $29
Current: $2.27
Upside: n/a
Apr 20, 2021
Initiated Coverage: Buy
Price Target: $51
Current: $1.17
Upside: n/a
Dec 9, 2020
Initiated Coverage: Buy
Price Target: $60
Current: $4.19
Upside: n/a